The percentage of measured prostate-specific antigen (free/total PSA ratio) is useful in assessing the risk of prostate cancer in patients with borderline or moderately increased total PSA (4.0-10.0 ng/mL) and has been used to help select men who should have follow-up prostate biopsy10. This evidence concerns the gene KLK3 and prostate carcinoma.